CRISMO

Executive Summary

CRISMO is a preclinical-stage biotechnology company based in Cape Town, South Africa, dedicated to developing CRISPR-based gene editing therapies for genetic disorders and infectious diseases. Founded in 2018, the company leverages its expertise in CRISPR technology to address high unmet medical needs in both rare genetic conditions and infectious diseases prevalent in Africa and globally. As a private company with 10-50 employees, CRISMO operates in an early development phase with no disclosed funding rounds or valuation estimates. Its focus on gene editing positions it within a rapidly evolving and competitive landscape, but its South African base may offer unique advantages in addressing regional health challenges and accessing local research collaborations. The company has yet to publish clinical data or pipeline details, indicating significant development risk and timeline uncertainty.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Round40% success
• Q4 2026Preclinical Proof-of-Concept Data Release30% success
• Q2 2026Research Collaboration with Academic Institution25% success